CRISPR breakthrough reverses chemotherapy resistance in lung cancer

In a major step forward for cancer care, investigators at ChristianaCare’s Gene Editing Institute have shown that disabling the NRF2 gene with CRISPR technology can reverse chemotherapy resistance in lung cancer. The approach restores drug sensitivity and slows tumor growth. The findings are published in the journal Molecular Therapy Oncology.

Source: https://medicalxpress.com/news/2025-11-crispr-breakthrough-reverses-chemotherapy-resistance.html